questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
Diagnostic
5
Kinases
Signalisation cellulaire
Protéomique
Phosphorylation
Cancers
Maladies inflammatoires
Symptômes
5
Système immunitaire
Réponse immunitaire
Éruptions cutanées
Troubles métaboliques
Troubles neurologiques
Dysfonction
Stress cellulaire
Apoptose
Prévention
5
Mode de vie sain
Nutrition
Tabagisme
Graisses saturées
Traitements
5
Thérapie génique
Mutations
Médicaments
Inhibiteurs de MEK
Plantes médicinales
Signalisation
Complications
5
Complications
Inflammation chronique
Maladies auto-immunes
Anomalies
Cancer
Activation aberrante
Risques cardiovasculaires
Maladies cardiovasculaires
Vieillissement
Dysfonctionnements
Facteurs de risque
5
Âge
Signalisation cellulaire
Prédispositions génétiques
Mutations
Mode de vie sédentaire
Mauvaise alimentation
Infections virales
Perturbation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes",
"headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extracellular Signal-Regulated MAP Kinases",
"url": "https://questionsmedicales.fr/mesh/D048049",
"about": {
"@type": "MedicalCondition",
"name": "Extracellular Signal-Regulated MAP Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3",
"alternateName": "Mitogen-Activated Protein Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048052",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Wang",
"url": "https://questionsmedicales.fr/author/Juan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35948846",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11030-022-10509-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35741107",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells11121978"
}
},
{
"@type": "ScholarlyArticle",
"name": "Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37441071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1183215"
}
},
{
"@type": "ScholarlyArticle",
"name": "Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35684392",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27113454"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.",
"datePublished": "2022-07-13",
"url": "https://questionsmedicales.fr/article/35911744",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.953761"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "Extracellular Signal-Regulated MAP Kinases",
"item": "https://questionsmedicales.fr/mesh/D048049"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitogen-Activated Protein Kinase 3",
"item": "https://questionsmedicales.fr/mesh/D048052"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3",
"description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitogen-Activated Protein Kinase 3",
"description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitogen-Activated Protein Kinase 3",
"description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitogen-Activated Protein Kinase 3",
"description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitogen-Activated Protein Kinase 3",
"description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3",
"description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de MAPK3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer MAPK3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de phosphorylation et les analyses protéomiques sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à MAPK3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des cancers et des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner une inflammation et des douleurs."
}
},
{
"@type": "Question",
"name": "MAPK3 affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à MAPK3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de MAPK3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour MAPK3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter MAPK3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Des exercices spécifiques aident-ils MAPK3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3."
}
},
{
"@type": "Question",
"name": "La gestion du poids influence-t-elle MAPK3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent MAPK3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger MAPK3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la voie MAPK3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour MAPK3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle MAPK3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment MAPK3 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "MAPK3 peut-elle influencer le vieillissement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à MAPK3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'activité de MAPK3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il MAPK3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter MAPK3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber la signalisation de MAPK3."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/02/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Institute for Zellbiochemie, Medizinische Hochschule Hannover (MHH), Hanover, Germany (M.G.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. feizhang@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Division of Gastroenterology, Department of Medicine Jichi Medical University School of Medicine Shimotsuke Tochigi Japan.
Publications dans "Mitogen-Activated Protein Kinase 3" :
Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) plays an important role in negative regulating immunity. The search for effective PD-1/PD-L1 inhibitors has been a...
Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality. Immune checkpoint mo...
Natural Killer cells (NKs) represent the innate counterpart of TCRαβ lymphocytes and are characterized by a high anti-tumor and an anti-viral cytotoxic activity. Recently, it has been demonstrated tha...
In this study, we analyzed the expression and function of PD-1 on Cord Blood derived NKs (CB-NKs) on a large cohort of newborns through multiparametric cytofluorimetric analysis....
We identified PD-1 on CB-NKs in more than of half the newborns analyzed. PD-1 was present on CD56...
To our understanding, this study is the first to report PD-1 expression on CB derived NKs and its features in perinatal conditions. These data may prove important in selecting the most suitable CB der...
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/P...
An influx of systematic reviews (SRs) of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in cancer treatment with or without meta-analysis and with different...
A comprehensive search of SRs, which included meta-analyses of PD-(L)1 inhibitors on cancer, was performed on eight databases with a cutoff date of 1 January 2022. Two authors independently identified...
A total of 172 SRs with meta-analysis met the inclusion criteria. The report quality of included SRs was quite good, with 128 (74.42%) SRs of high quality and 44 (25.58%) of moderate quality. The meth...
PD-(L)1 inhibitors appeared to be effective and safe for cancer treatment, except for gastrointestinal tumors; however, the quality of the evidence is not convincing. Future studies should improve met...
http://www.crd.york.ac.uk/prospero, identifier CRD42020194260....
Programmed death receptor 1 (PD-1) is an inhibitory receptor on T cells shown to restrain T-cell proliferation. PD-1 immune checkpoint blockade has emerged as a highly promising approach in cancer tre...
A series of novel compounds bearing a cyclopropyl linkage were designed, synthesized, and evaluated as programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. An optimized co...
Multiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unc...
We used bidirectional two-sample Mendelian randomization with two different thresholds to explore the potential causal relationship between the microbiota and PD-1/PD-L1 and species-level microbiota G...
In the primary forward analysis, genus_Holdemanella showed a negative correlation with PD-1 [βIVW = -0.25; 95% CI (-0.43 to -0.07); P...
Checkpoint blockade of the immunoreceptor programmed cell death-1 (PD1) with its ligand-1 (PDL1) by monoclonal antibodies such as pembrolizumab provided compelling clinical results in various cancer t...
Preeclampsia is a pregnancy-specific disease which is characterized by abnormal placentation, endothelial dysfunction, systemic inflammation and disruption of the immune system. The goal of this study...